|Post IPO Valuation|
|Description||A specialty pharma company|
|Series B, 5/2012 |
|Partial Close, 9/2013 |
Egalet Ltd. is a specialty pharma company focusing on pain management. Based on the Egalet technology, the company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.